A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: A prospective phase II GINECO trial

Supportive Care in Cancer

Volumn 21, Issue 7, 2013, Pages 1947-1954

  Weber, Béatrice ^a   Largillier, Rémy ^b   Ray Coquard, Isabelle ^c   Yazbek, Gabriel ^d   Meunier, Jérôme ^e   Alexandre, Jérôme ^f   Dauba, Jérôme ^g   Spaeth, Dominique ^h   Delva, Rémy ⁱ   Joly, Florence ^j   Pujade Lauraine, Eric ^f   Copel, Laure ^k  

^a CENTRE ALEXIS VAUTRIN   (France)

^b Centre Azureen de Cancerologie   (France)

^c CENTRE LÉON BÉRARD   (France)

^d INSTITUT JEAN GODINOT   (France)

^e CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^f HÔTEL DIEU   (France)

^g Mont de Marsan Hospital   (France)

^h Centre d'Oncologie de Gentilly   (France)

ⁱ UMR INSERM U892 CNRS 6299   (France)

^j CENTRE FRANÇOIS BACLESSE   (France)

^k INSTITUT CURIE   (France)

more..

Author keywords

Erythropoietin; FACT GOG Ntx; Neuroprotective; Neurotoxicity; Paclitaxel

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; ERYTHROPOIETIN; IRON; PACLITAXEL; PLATINUM COMPLEX; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD CELL COUNT; CANCER PATIENT; CANCER STAGING; CORRELATION COEFFICIENT; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; FRANCE; HEMOLYSIS; HISTOPATHOLOGY; HUMAN; INTERNAL CONSISTENCY; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; OVARY CANCER; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ERYTHROPOIETIN; FEMALE; FRANCE; HUMANS; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; OVARIAN NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES; QUESTIONNAIRES; TRANSLATIONS;

EID: 84878738407     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1748-0     Document Type: Article

References (29)

1. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320-1329
2. du Bois A, Neijt JP, Thigpen JT (1999) First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care? Ann Oncol 10(Suppl 1):35-41
3. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18(17):3084-3092
4. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361(9375):2099-2106
5. Ozols RF (2000) Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol 27(3 Suppl 7):47-49
6. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249(1):9-17
7. Guastalla JP 3rd, Dieras V (2003) The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer 89(Suppl 3):S16-S22
8. Bernaudin M, Bellail A, Marti HH, Yvon A, Vivien D, Duchatelle I, Mackenzie ET, Petit E (2000) Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 30(3):271-278
9. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R (1997) Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76(1):105-116
10. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, Lauria G, Borgna M, Lombardi R, Cimen B, Comelekoglu U, Kanik A, Tataroglu C, Cerami A, Ghezzi P (2004) Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 101(3):823-828
11. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren AL (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8(8):495-505
12. Hassan K, Simri W, Rubenchik I, Manelis J, Gross B, Shasha SM, Kristal B (2003) Effect of erythropoietin therapy on polyneuropathy in predialytic patients. J Nephrol 16(1):121-125
13. Mangiameli A, Spina S, Iannetti E, Catalano D, Spadaro D, Trovato GM (2002) [Erythropoietin and cisplatin-induced neuropathies in cancer patients] in Italian. Clin Ter 153(3):177-180
14. De Vos FY, Bos AM, Schaapveld M, de Swart CA, de Graaf H, van der Zee AG, Boezen HM, de Vries EG, Willemse PH (2005) A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol 97(1):60-67
15. Markman M, Glass T, Smith HO, Hatch KD, Weiss GR, Taylor SA, Goodwin JW, Alberts DS (2003) Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial. Gynecol Oncol 88(3):282-288
16. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB (2004) Phase III randomized trial of docetaxel- carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96(22):1682-1691
17. Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, Kaye SB (1998) Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 41(2):161-166
18. Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741-748
19. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH (2009) Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17(12):1483-1491
20. Huang HQ, Brady MF, Cella D, Fleming G (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17(2):387-393
21. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS, American Society of Clinical Oncology. American Society of Hematology (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20(19):4083-4107
22. Rosales RS, Delgado EB, Diez de la Lastra-Bosch I (2002) Evaluation of the Spanish version of the DASH and carpal tunnel syndrome health-related quality-of-life instruments: cross-cultural adaptation process and reliability. J Hand Surg Am 27(2):334-343
23. Collins MM, O'Leary MP, Calhoun EA, Pontari MA, Adler A, Eremenco S, Chang CH, Odom L, Litwin MS (2001) The Spanish National Institutes of Health-Chronic Prostatitis Symptom Index: translation and linguistic validation. J Urol 166(5):1800-1803
24. Tubiana-Rufi N, Bean K, Moret L, Czernichow P, Chwalow AJ (1992) [French-language adaptation of an evaluation test of knowledge meant for insulin-dependent children: methodology and value for research in clinical practice] in French. Rev Epidemiol Sante Publique 40(3):191-200
25. Boscainos PJ, Sapkas G, Stilianessi E, Prouskas K, Papadakis SA (2003) Greek versions of the Oswestry and Roland-Morris Disability Questionnaires. Clin Orthop Relat Res 411:40-53
26. Sloan JA, Cella D, Hays RD (2005) Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol 58(12):1217-1219
27. Driessen CM, de Kleine-Bolt KM, Vingerhoets AJ, Mols F, Vreugdenhil G (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20(4):877-881
28. Bianchi R, Gilardini A, Rodriguez-Menendez V, Oggioni N, Canta A, Colombo T, De Michele G, Martone S, Sfacteria A, Piedemonte G, Grasso G, Beccaglia P, Ghezzi P, D'Incalci M, Lauria G, Cavaletti G (2007) Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer 43(4):710-717
29. Cervellini I, Bello E, Frapolli R, Porretta-Serapiglia C, Oggioni N, Canta A, Lombardi R, Camozzi F, Roglio I, Melcangi RC, D'Incalci M, Lauria G, Ghezzi P, Cavaletti G, Bianchi R (2010) The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats. Neurotox Res 18(2):151-160